Faces, the leading beauty destination for all of your fragrance, skincare and makeup desires presents you with an array of fragrances this Valentine’s Day!

Valentine’s Day is a day of sharing with loved ones, a day of pampering and telling those that are close to you how much they mean to you.

What better than the gift of Beauty to express your love and care?! At Faces, we have the newest romantic and feminine fragrances to offer to your loved ones and show them how special they are…and why not pick up a little something for yourself as well?

Play Sport by Givenchy

An emblematic sport fragrance. Boosted by the spicy freshness of citrus, mint and ginger, Play Sport’s heart notes of Amyris wood recall the sensuality and manliness of the PLAY franchise.

Hot water by Davidoff

Herein lays an erotic masculine virtue and a sensual warmth. The vibrant Red Basil and Absinthe top-note thrillingly grounded by the genuine class of Wormwood. An amatory heart-note of burning Pimento. An ultra-masculine dry-down of Benzoin Siam. Hot Water is fresh, spicy and jubilant.

Romantina by Juliette Has a Gun

Romantina is a musky composition in which we have delicately laid a bouquet of white flowers. An ode to Insouciance…Where Orange Blossom impulsively marries Jasmine; the Rose passionately blends with Iris and Osmanthus.

CH by Carolina Herrera

Fresh and floral! This is how Carolina likes to define her creation!

Nina L’Elixir by Nina Ricci

Nina L’Elixirevokes the rare and luxurious essence of a love potion, concentrated in an Eau de Parfum. An intense reinterpretation of Nina Eau de Toilette.

Lacoste Joy of Pink

The LACOSTE Pink woman exudes an aura of feel good, youthful optimism, and Joy Of Pink is the ideal fragrance to awaken the happiness and confidence she feels in social situations with her closest companions.

Chopard Happy Spirit Elixir D’Amour

Fullness and femininity are the signatures of the Happy Spirit Elixir D’Amour fragrance – a lush floral composition in which the voluptuous heart note of nobleJasmine Sambac is enlightened by delicate touches of Yellow Freesia, and rounded outby a lingering dry-down of Amber, White Musk and Cashmere Wood.

Discover these and other Beauty treats at Faces this Valentine’s Day!

Faces…your Beauty Vibes

Contacts

Joyce Amil

Euro RSCG Corporate Communications

joyce.amil@eurorscgme.com

Tel: +97 1 4 455 6000

Phase III soft tissue sarcoma trial ongoing; randomized Phase II pancreatic cancer trial expected to report in February 2012
Deal provides Threshold with an upfront payment of € 19 million ($25 million), plus further potential milestones and royalties as well as an option to co-commercialize in the United States

-(BUSINESS WIRE)– Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug. TH-302 is currently being investigated in a global Phase III clinical trial in patients with soft tissue sarcoma, a randomized Phase II trial in patients with advanced pancreatic cancer from which top-line results are expected in February, as well as additional clinical studies in other solid tumors and hematological malignancies.

Under the terms of the agreement, Merck will receive co-development rights, exclusive global commercialization rights and will provide Threshold an option to co-commercialize the therapeutic in the United States. In exchange, Threshold will receive an upfront payment of € 19 million ($25 million) and could receive up to € 26.5 million ($35 million) in additional development milestones during 2012. Threshold is also eligible to receive a € 15 million ($20 million) milestone payment based on positive results from its randomized Phase II trial in pancreatic cancer.

In the United States, Threshold will have primary responsibility for development of TH-302 in the soft tissue sarcoma indication. Threshold and Merck KGaA will jointly develop TH-302 in all other cancer indications being pursued. Merck KGaA will pay 70% of worldwide development costs for TH-302.

Subject to FDA approval in the United States, Merck KGaA will initially be responsible for commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales. Under the royalty-bearing portion of the agreement, Threshold retains the option to co-promote TH-302 in the United States. Additionally, Threshold retains the option to co-commercialize TH-302 allowing the company to participate in up to 50% of the profits in the United States, based on certain revenue tiers. Outside of the United States, Merck KGaA will be solely responsible for the commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales in these territories.

“The addition of TH-302 to our pipeline provides an important opportunity in several different tumor types to expand our oncology development program,” said Susan Jane Herbert, Head of Global Business Development and Strategy, Merck Serono. “Given the fact that pancreatic cancer is a very difficult to treat indication, successful Phase II results could represent important upside for our company.”

“We are excited by the new resources that our partnership is going to bring to the development of TH-302, and the expertise in clinical development and commercialization that Merck will contribute to this program,” said Barry Selick, President and CEO of Threshold. “This collaboration provides Threshold a strong and committed partner with a shared vision for TH-302.”

TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark for many cancer indications. Areas of low oxygen levels (hypoxia) within tissues are common in many solid tumors due to insufficient blood vessel growth. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be extremely hypoxic.

TH-302 has been investigated in over 550 patients in Phase I/II clinical trials to date in a broad spectrum of tumor types, both as a monotherapy and in combination with chemotherapy treatments and other targeted cancer drugs.

Threshold has several ongoing clinical trials including, but not limited to: a controlled Phase II trial of TH-302 in combination with gemcitabine versus gemcitabine alone in patients with advanced pancreatic cancer and a Phase III study evaluating TH-302 in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma.

TH-302 development in soft tissue sarcoma

A Phase III trial of TH-302 in patients with first-line advanced soft tissue sarcoma (STS) was initiated in September, 2011, based on results from a Phase I/II trial investigating its use in combination with the chemotherapeutic doxorubicin. This randomized, multi-center Phase III trial will investigate the use of TH-302 plus doxorubicin compared with doxorubicin alone. The primary efficacy endpoint is overall survival. The study is conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration. It is being run in partnership with the Sarcoma Alliance for Research through Collaboration (SARC) and aims to enroll 450 patients with metastatic or locally advanced unresectable STS.

TH-302 development in pancreatic cancer

Results from a randomized, controlled, multi-center Phase II trial of TH-302 in patients with first-line pancreatic cancer are expected to be announced in February, 2012. This trial of 214 previously untreated patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma started in June, 2010, and completed enrollment in June, 2011. Two different doses of TH-302 in combination with the chemotherapeutic gemcitabine were compared to gemcitabine alone, with progression free survival (PFS) as the primary endpoint.

Soft tissue sarcoma

STS refers to a heterogeneous and relatively rare group of tumors that develops in the soft, supporting tissues of the body. It can occur in any of the tissues that support, surround or protect the organs of the body, such as muscle, fat, nerves, tendons and ligaments or blood vessels. It can also develop in specific organs including, for example, the uterus, stomach, skin and small bowel. Occasionally it occurs in the head and neck. Adult STS is rare, with an estimated average incidence of 4 in 100,000 cases in Europe annually.1 In the United States, there were an estimated 10,980 new cases and 3,920 deaths from STS in 2011.2 STS tends to occur in people over the age of 30, although certain types of sarcoma can develop more commonly in children and teenagers.3 Current treatment options for STS include surgery, chemotherapy and radiotherapy, although response rates are generally low and side effects can be significant.

Pancreatic cancer

Pancreatic cancer is considered fairly rare, particularly in younger people. The most common symptoms are pain in the upper abdomen, weight loss, and jaundice. Current treatment options include surgery, radiotherapy and chemotherapy. It is estimated that approximately 279,000 cases of pancreatic cancer were diagnosed worldwide in 2008.4

References

1 Casali, PG et al on behalf of the ESMO Guidelines Working Group. Ann Oncol. 2010;20(4):iv132-iv136

2.National Cancer Institute. Snapshot of Sarcoma. 2011; http://www.cancer.gov/aboutnci/servingpeople/snapshots/sarcoma.pdf. Last accessed January 13, 2011.

3.Macmillan Cancer Support: http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Softtissuesarcomas/Softtissuesarcomas.aspx. Last accessed January 16, 2011.

4. GLOBOCAN 2008. World estimated cancer incidence, all ages: both sexes. http://globocan.iarc.fr/summary_table_pop.asp?selection=221900&title=World&age_from=1&age_to=10&sex=0&type=0&PDF=1&window=1&sort=0&submit=%A0Execute%A0Last accessed February 1, 2012.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of patients with some hematologic malignancies. For additional information, please visit the company’s website: www.thresholdpharm.com.

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. In the United States and Canada, EMD Serono operates as a separately incorporated affiliate of Merck Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride), (Egrifta®, tesamorelin), as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets.

With an annual R&D expenditure of over € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in rheumatology.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of € 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.comor www.merckgroup.com

Contacts

Dr. Raphaela Farrenkopf

Phone +49 6151-72 2274

raphaela.farrenkopf@merckgroup.com

MelApp Named One of the Top Ten Apps that can Save Your Life in Parade Magazine

(BUSINESS WIRE)– Health Discovery Corporation (OTCBB: HDVY), the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment, today debuts its popular MelApp mobile app for Android™ devices. Now, health-conscious consumers can easily learn about melanoma and identify areas on their skin which may need attention from a specialist, anytime, anywhere with their iPhone, iPod Touch and iPad, as well as Android smartphone.

First launched this summer for iPhone, MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. The app was validated using an image database licensed from Johns Hopkins University Medical Center and uses a device’s camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. In addition, MelApp can use the smartphone’s GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical diagnosis and treatment.

“Being currently used in nearly 50 countries, and having been named one of the ‘Top 10 Apps That Could Save Your Life’in a recent issue of Parade Magazine, MelApp has become a worldwide success,” stated Stephen D. Barnhill, M.D. Chairman and CEO of Health Discovery Corporation. “With the launch of MelApp for Android our goal was to extend the availability of this easy to use, inexpensive and potentially life-saving app to the more than 46 percent of the smart phone market that use Android devices, according to Nielsen.”

Now available for iPhone, iPod touch, and iPad, as well as for Android, MelApp is available for download at a special limited time price of $1.99 at the following app marketplaces:

iTunes App Store – http://itunes.apple.com/us/app/melapp/id446669257?mt=8&ls=1
Android Marketplace – https://market.android.com/search?q=MelApp&c=apps

This version of MelApp for Android has been optimized for the Droid X. For support and technical inquiries, contact support@healthdiscoverylabs.com.

Physicians who diagnose and treat melanoma can become a subscribing member of HDC’s physician referral network by contacting melappreferral@healthdiscoverycorp.com.

About MelApp & Health Discovery Corporation

MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze the uploaded image. MelApp was validated using an image database licensed from Johns Hopkins University Medical Center and uses a device’s camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. The app can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up. MelApp by Health Discovery Corporation is available at a special limited time introductory price of $1.99. For more complete details, visit http://www.melapp.net, http://www.facebook.com/MelAppor http://twitter.com/#!/SafeHealthApps.

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Contacts

Health Discovery Corporation

Colleen Murphy, 404-214-0722 Ext. 109

cmurphy@trevelinokeller.com

New treatment combines DPP-4 inhibitor, linagliptin (the active ingredient in Trajenta™ [linagliptin] tablets), and metformin in a single tablet, taken twice-daily, to lower blood glucose in adults with Type 2 Diabetes

(BUSINESS WIRE)–For Non-U.S. and Non-UK Media

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company(NYSE: LLY) have announced that the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.1 Linagliptin/metformin hydrochloride (HCl) provides a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.1 Linagliptin (5 mg, once-daily) is marketed in the U.S. as Tradjenta™ (linagliptin) tablets, as Trajenta™ across Europe and Canada, and Trazenta™ in Japan, as well as in further markets.2,3

Linagliptin/metformin HCl is a prescription medication used along with diet and exercise to improve glycaemic control in adults with Type 2 Diabetes when treatment with both linagliptin and metformin is appropriate. At the maximum dose, linagliptin/metformin HCl demonstrated placebo-corrected reductions in haemoglobin A1c (HbA1c or A1C) levels of up to 1.7 percent (+0.1 percent for placebo and -1.6 percent for linagliptin/metformin HCl). A1C is measured in people with diabetes to provide an index of blood glucose control for the previous two to three months. Linagliptin/metformin HCl did not cause any meaningful change in body weight. Linagliptin/metformin HCl can be used alone or in combination with a sulphonylurea, a commonly prescribed medication for Type 2 Diabetes. Linagliptin/metformin HCl are not for the treatment of Type 1 Diabetes or diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin. The linagliptin/metformin HCl label contains a boxed warning for the risk of lactic acidosis, a serious metabolic complication that can occur due to metformin accumulation during treatment with linagliptin/metformin HCl.1

“Most people with Type 2 Diabetes require more than one medication to help lower their blood sugar, due to the complex nature of Type 2 Diabetes,” said Dr. Lance Sloan, Texas Institute for Kidney and Endocrine Disorders. “The approval of Jentadueto™ is exciting because it combines two diabetes medications in a single tablet, making it a good option for people who need an additional medication, and for whom both linagliptin and metformin is appropriate.”

Linagliptin/Metformin HClClinical Trials

In a 24-week, randomised, double-blind, placebo-controlled factorial study evaluating 791 adults with Type 2 Diabetes and inadequate glycaemic control with diet and exercise, linagliptin plus metformin demonstrated the following:1

Placebo

5 mg linagliptin once-daily

500 mg metformin twice-daily

2.5 mg linagliptin/ 500 mg metformin twice-daily

1,000 mg metformin twice-daily

2.5 mg linagliptin/ 1,000 mg metformin twice-daily

A1C (%)

Change from baseline (adjusted mean)

+0.1

-0.5

-0.6

-1.2

-1.1

-1.6

Difference from placebo (adjusted mean)

–

-0.6

-0.8

-1.3

-1.2

-1.7

*FPG (mg/dL)

Change from baseline (adjusted mean)

+10

-9

-16

-33

-32

-49

Difference from placebo (adjusted mean)

–

-19

-26

-43

-42

-60

Glycaemic parameters at final visit (24-week study) for linagliptin and metformin, alone and in combination in randomised adults with Type 2 Diabetes Mellitus inadequately controlled on diet and exercise (full analysis population using last observation on study)

*Fasting plasma glucose (FPG) is used to determine glucose levels in a fasting state (usually upon waking in the morning).

Linagliptin/metformin HCl tablets were approved based on clinical trials that evaluated linagliptin and metformin as separate tablets. Bioequivalence of linagliptin/metformin HCl was demonstrated with co-administered linagliptin and metformin tablets in healthy subjects.1

Adverse reactions reported in greater than or equal to five percent of patients treated with linagliptin/metformin HCl and more commonly than in patients treated with placebo included nasopharyngitis (the common cold) and diarrhoea. Hypoglycaemia was more commonly reported in patients treated with the combination of linagliptin/metformin HCl and sulphonylurea compared with those treated with the combination of placebo, sulphonylurea and metformin (22.9 percent versus 14.8 percent, respectively). Pancreatitis was reported more often in patients randomised to linagliptin (1 per 538 person years versus zero in 433 person years for comparator).1

“We are proud to bring this important, new treatment option combining linagliptin and metformin hydrochloride as a single-tablet, taken twice-daily, to the millions of people currently living with Type 2 Diabetes,” said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “We are hopeful that Jentadueto™, the newest member of the growing family of products from the Boehringer Ingelheim and Lilly diabetes alliance, will help people living with blood glucose levels that are not adequately controlled.”

The FDA approval of linagliptin/metformin HCl marks the second U.S. approval since the formation of the Boehringer Ingelheim and Eli Lilly and Companyworldwide diabetes alliance in January 2011. The alliance leverages the collective scientific expertise and business capabilities of two leading research-driven pharmaceutical companies to address patient needs arising from the growing global diabetes epidemic.

About linagliptin/metformin HCl

Linagliptin/metformin HCl is a prescription medicine that contains two diabetes medicines, linagliptin and metformin. Linagliptin/metformin HCl can be used along with diet and exercise to help control blood glucose in adults with Type 2 Diabetes when treatment with both linagliptin and metformin is appropriate.1

Linagliptin/metformin HCl is not for people with Type 1 Diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).1

It is not known if linagliptin/metformin HCl is safe and effective when used with insulin.1

About Linagliptin

Linagliptin is an inhibitor of the enzyme DPP-4 (dipeptidyl peptidase-4) which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide). Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion thus resulting in an overall improvement in the glucose homoeostasis.3

Linagliptin (5 mg, once-daily) is marketed in the U.S. as Tradjenta™, as Trajenta™ across Europe and Canada, and Trazenta™ in Japan, as well as in further markets.2,3

Linagliptin is a prescription medicine that is used along with diet and exercise to lower blood glucose in adults with Type 2 Diabetes.2,3 Linagliptin is not for people with Type 1 Diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).2,3 It is not known if linagliptin is safe and effective when used with insulin.2,3

About Diabetes

An estimated 366 million people worldwide have diabetes.4 Type 2 Diabetes is the most common type, accounting for an estimated 90 percent of all diabetes cases.4 Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.5

Boehringer Ingelheim and Eli Lilly and Company

In January 2011, Boehringer Ingelheim and Eli Lilly and Companyannounced an alliance in the field of diabetes that centres on four pipeline compounds representing several of the largest treatment classes. This alliance leverages the companies’ strengths as two of the world’s leading pharmaceutical companies, combining Boehringer Ingelheim’s solid track record of research-driven innovation and Lilly’s innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.comor www.lilly.com.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24 percent of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world’s first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy – practical tools, education, and support programmes to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit www.lillydiabetes.com.

This press release contains forward-looking statements about linagliptin and linagliptin/metformin HCl tablets for the treatment of Type 2 Diabetes. It reflects Lilly’s current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that linagliptin will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly’s latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

###

1. Jentadueto™ (linagliptin/metformin HCI) tablets. Highlights of Prescribing Information. Initial US Approval: 2012 2. Tradjenta™ (linagliptin) tablets. Highlights of Prescribing Information. Initial U.S. Approval: 2011. 3. Trajenta™ (linagliptin) tablets. EMA Summary of Product Characteristics. Approval 25 September 2011. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf 4. International Diabetes Federation. Diabetes Atlas 5th edn. www.idf.org, 2010. 5. World Health Organization: Fact Sheet No. 312 What is Diabetes?, 2010.

Contacts

Boehringer Ingelheim GmbH

Arnd Prilipp

Email: press@boehringer-ingelheim.com

Phone: +49 (6132) 77-97296

Lilly Diabetes

Tammy Hull

Communications Manager

Email: hullta@lilly.com

Phone: +1 (317) 651-9116

MANSFIELD, Mass. – Monday, January 30th 2012 [ME NewsWire]

(BUSINESS WIRE)– Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the Solitaire™ FR Revascularization Device has been approved for investigational use in the Interventional Management of Stroke (IMS III) trial. The Solitaire FR device was approved by the IMS III Executive Committee in the thrombectomy arm of the trial and was included in a recently approved amendment submitted to the U.S. Food and Drug Administration (FDA).

The IMS III Trialwill compare a combined intravenous (IV) and intra-arterial (IA) treatment approach to restoring blood flow to the brain to the current standard FDA-approved treatment approach of giving IV rTPA alone. A projected 900 subjects with moderate to severe ischemic stroke will be enrolled at over 50 centers in the United States, Canada, Australia and potentially Europe.The Executive Committee approved the Solitaire FR device to ensure that the study and patients have the most advanced treatment technologies to help determine the role of endovascular therapy in acute ischemic stroke.

“We are excited to include the Solitaire FR Revascularization Device in the National Institute of Neurological Disorders and Stroke-funded IMS III trial. The addition of the device will help to expedite the completion of this critical trial,” said Dr. Joseph Broderick, IMS III Principal Investigator, Professor and Chair of the Department of Neurology, University of Cincinnati.

Outside the United States, the Solitaire FR device has become the leading technology for the endovascular treatment of acute ischemic stroke, providing stroke physicians with an innovative treatment technology over the existing options. The high success rate, fast procedure time and ease of use experienced by physicians in Europe and other regions who have used the device led physicians to request that it be included in the IMS III Trial.

“The Solitaire FR is the first stent-based mechanical thrombectomy device allowed into the study by IMS III investigators,” said Mark A. Turco, MD, Chief Medical Officer, Vascular Therapies, Covidien. “We look forward to the important results that will follow from this study around the optimal treatment of acute ischemic stroke.”

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.comto learn more about our business.

Contacts

Vascular Therapies

Rachel Bloom-Baglin, 508-261-6651

Vice President, Communications

rachel.bloombaglin@covidien.com

Bruce Farmer, 508-452-4372

Vice President

Public Relations

bruce.farmer@covidien.com

Cole Lannum, CFA, 508-452-4343

Vice President

Investor Relations

cole.lannum@covidien.com

Todd Carpenter, 508-452-4363

Director

Investor Relations

todd.carpenter@covidien.com

(BUSINESS WIRE)– Pantene, the world’s leading haircare brand, today announced it will support 11 elite female athletes as its newest beauty ambassadors. The group will be featured in Pantene’s first global marketing campaign to support the Olympic Games. The athletes will provide proof that, regardless of their training for the Olympic Games, Pantene’s performance helps give them beautiful hair.

The sponsorship is part of P&G’s Worldwide Olympic Partner status with the London 2012 Olympic Games and marks the first time Pantene has featured athletes as beauty ambassadors. The group will join the likes of celebrities such as Liv Tyler and Eva Mendes, who are featured in Pantene’s iconic campaigns. Among the athletes are six Olympic gold medalists, numerous world champions and top ranked women in swimming, tennis, gymnastics, cycling, diving and volleyball.

“I spend hours in the pool and I want my hair to look beautiful,” said 11-time U.S. Olympic medalist Natalie Coughlin, one of the Pantene-sponsored athletes. “I trust Pantene to make my hair look great so I can concentrate on training.”

“We believe that healthy is the new beautiful and we’re thrilled to add this exceptional group to our select list of global beauty ambassadors. These women are a wonderful fit with our heritage of performance and shine,” said Hanneke Faber, Vice President and Brand Franchise Leader, Global Haircare at P&G. “Their hair is easily some of the most challenged on the planet and Pantene can take on the task. Our products are designed to perform under demanding conditions.”

Pantene’s athlete roster includes*:

Jaqueline Carvalho

Brazil

Volleyball

Beijing 2008 Olympic Games gold medalist and Brazilian National Team striker

Natalie Coughlin

United States

Swimming

11-time Olympic medalist and multiple international competition medalist

Gisela Dulko

Argentina

Tennis

Top ranked global doubles player

Paola Espinosa

Mexico

Diving

Two-time Olympian and Beijing 2008 Olympic Games bronze medalist

Evgeniya Kanaeva

Russia

Rhythmic Gymnastics

2008 Olympic gold medalist

Wu Minxia

China

Diving

Two-time Olympic gold medalist and three-time world champion

Victoria Pendleton

Great Britain

Cycling

Olympic gold medalist and eight-time world champion

Annamay Pierse

Canada

Swimming

Olympian and world record holder in the 200m breast stroke

Aya Terakawa

Japan

Swimming

International competition medalist and Athens 2004 Olympic Games participant

*Additional athletes to be named later

The Pantene campaign leading up to and during London 2012 includes holistic and integrated support in advertising, retail, online and PR channels. It is part of P&G’s Worldwide Olympic Partner status, which is anchored by the ‘Thank You, Mom’ campaign for the London 2012 Olympic Games. P&G’s ‘Thank You Mom’ campaign will help improve life for moms around the world and provide support for the moms of the Pantene athletes and the moms of thousands of other Olympians. For more information on the brand’s activities, visit www.pantene.com.

About P&G

P&G touches and improves the lives of about 4.4 billion people around the world with its portfolio of trusted, quality brands. The Company’s leadership brands include Pampers®, Tide®, Ariel®, Always®, Whisper®, Pantene®, Mach3®, Bounty®, Dawn®, Fairy®, Gain®, Pringles®, Charmin®, Downy®, Lenor®, Iams®, Crest®, Oral-B®, Duracell®, Olay®, Head & Shoulders®, Wella®, Gillette®, Braun®, Fusion®, Ace®, Febreze®, and Ambi Pur®. With operations in about 80 countries, P&G brands are available in more than 180 countries worldwide. Please visit http://www.pg.comfor the latest news and in-depth information about P&G and its brands.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50145935&lang=en

Photo Captions:

Image 1: Pantene, the world’s leading haircare brand, will support 11 elite female athletes as its newest beauty ambassadors. The group will be featured in Pantene’s first global marketing campaign to support the Olympic Games. The athletes will provide proof that, regardless of their training for the Olympic Games, Pantene’s performance helps give them beautiful hair. (Photo: Business Wire)

Image 2: Pantene, the world’s leading haircare brand, will support 11 elite female athletes as its newest beauty ambassadors. The group will be featured in Pantene’s first global marketing campaign to support the Olympic Games. The athletes will provide proof that, regardless of their training for the Olympic Games, Pantene’s performance helps give them beautiful hair. (Photo: Business Wire)

Image 3: Pantene, the world’s leading haircare brand, will support 11 elite female athletes as its newest beauty ambassadors. The group will be featured in Pantene’s first global marketing campaign to support the Olympic Games. The athletes will provide proof that, regardless of their training for the Olympic Games, Pantene’s performance helps give them beautiful hair. (Photo: Business Wire)

Image 4: Pantene, the world’s leading haircare brand, will support 11 elite female athletes as its newest beauty ambassadors. The group will be featured in Pantene’s first global marketing campaign to support the Olympic Games. The athletes will provide proof that, regardless of their training for the Olympic Games, Pantene’s performance helps give them beautiful hair. (Photo: Business Wire)

Image 5: Pantene, the world’s leading haircare brand, will support 11 elite female athletes as its newest beauty ambassadors. The group will be featured in Pantene’s first global marketing campaign to support the Olympic Games. The athletes will provide proof that, regardless of their training for the Olympic Games, Pantene’s performance helps give them beautiful hair. (Photo: Business Wire)

Image 6: Pantene, the world’s leading haircare brand, will support 11 elite female athletes as its newest beauty ambassadors. The group will be featured in Pantene’s first global marketing campaign to support the Olympic Games. The athletes will provide proof that, regardless of their training for the Olympic Games, Pantene’s performance helps give them beautiful hair. (Photo: Business Wire)

Contacts

Pantene

Randall Chinchilla, +1-513-626-5665

+1-513-780-7720

chinchilla.r@pg.com

Taylor

Mari Rella, +1-212-714-5744

+1-516-316-4611

mrella@taylorstrategy.com

Net sales up 5%; Medical Devices sales up 6%
First-quarter diluted GAAP earnings per share from continuing operations were $1.02; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.13, up 19%
Fiscal 2012 sales guidance updated

(BUSINESS WIRE)– Covidien plc (NYSE: COV) today reported results for the first quarter of fiscal 2012 (October-December 2011). First-quarter net sales of $2.90 billion increased 5% from the $2.77 billion reported a year ago. Foreign exchange rate movement had no impact on the quarterly sales growth rate.

First-quarter 2012 gross margin of 58.7% rose 2.0 percentage points from the 56.7% of the prior-year period. On an adjusted basis, first-quarter 2012 gross margin of 58.8% was at a record quarterly level, 1.2 percentage points above that of a year ago. This improvement reflected manufacturing cost reduction, benefits from our restructuring programs, favorable foreign exchange and positive business mix.

Selling, general and administrative expenses for the first quarter of 2012 were above those of the comparable quarter of the year before. This was due to higher legal charges and to spending on growth initiatives, primarily to expand the Company’s sales and marketing presence in emerging markets. Research and Development (R&D) expense in the first quarter climbed 21% and represented 5.0% of net sales, versus 4.3% of sales in the year-ago period.

In the first quarter of 2012, the Company reported operating income of $636 million, versus $549 million in the same period the year before. First-quarter 2012 adjusted operating income, excluding the specified items shown on the attached quarterly Non-GAAP reconciliations table, was $705 million, compared with $615 million in the previous year. First-quarter 2012 adjusted operating income, excluding the specified items, represented 24.3% of sales, versus 22.2% a year ago.

The first-quarter 2012 effective tax rate was 16.7%, versus an effective tax rate of 16.1% in the first quarter of 2011. The first-quarter 2012 adjusted tax rate, excluding specified items, was 17.4%, versus 18.4% in the first quarter a year earlier.

Diluted GAAP earnings per share from continuing operations were $1.02 in the first quarter of 2012, versus $0.87 per share in the comparable quarter last year. First-quarter 2012 adjusted diluted earnings per share, excluding specified items, were $1.13, versus $0.95 a year ago, a 19% increase.

“We are off to an excellent start in fiscal 2012, with good sales gains, record gross and operating margins and double-digit EPS growth,” said José E. Almeida, President and CEO. “This strong performance was again led by our largest business segment, Medical Devices, which delivered growth fueled by double-digit advances in Energy and Vascular products.

“During the first quarter, we also significantly increased R&D spending and continued to invest in our emerging markets, where sales again climbed at a double-digit pace,” Mr. Almeida said. “Looking forward, although we face some pressure on our reported results due to the recent strengthening of the U.S. dollar, we remain comfortable with the current annual consensus EPS estimates for 2012. We expect that our broad product portfolio, robust pipeline of new products and ongoing strategic investments funded by our strong cash flow will drive superior operational results for the remainder of 2012 and beyond.”

BUSINESS SEGMENT RESULTS

Medical Devicessales of $1.98 billion in the first quarter were 6% higher than the $1.88 billion in the comparable quarter of last year. Growth was driven by new products and increased volume. First-quarter sales in Endomechanical rose above those of the prior year, fueled by a good growth for stapling products, paced by our innovative Tri-Staple™ reloads. In Soft Tissue Repair, sales were slightly below those of a year ago, as an increase for sutures was more than offset by a decline for mechanical fixation and mesh products. Energy registered another strong double-digit quarterly sales gain, largely due to the continuation of exceptional growth in sales of vessel sealing products. In the Oximetry & Monitoring product line, growth was primarily attributable to higher sales of monitors. In Airway & Ventilation, sales were below those of the year before, as an increase in airway products was overshadowed by lower sales of ventilators. Vascular products posted sales well above those of the previous year, paced by double-digit increases for neurovascular and venous insufficiency products.

Pharmaceuticalssales of $490 million in the first quarter were up 4% from last year’s first-quarter sales of $470 million. Sales of Specialty Pharmaceuticals were slightly above those of a year ago, due to favorable generic pricing and growth for the EXALGO® and PENNSAID® products. Sales of Active Pharmaceutical Ingredients climbed 21%, driven by a sharp gain in narcotics, largely the result of customer order timing. Higher sales in Contrast Products reflected a one-time customer order and increased sales outside the United States. Sales of Radiopharmaceuticals were somewhat below those of the prior year, as higher generator sales were more than offset by lower sales of thallium and other products.

On December 15, 2011, the Company announced that it plans to spin off its pharmaceuticals business into a standalone public company. It anticipates that the transaction will be in the form of a distribution that will be tax-free to U.S. shareholders of a new publicly traded stock in the new pharmaceuticals company. Covidien currently expects that completion of the transaction could take up to 18 months. Earlier this month, the Company announced the appointment of Mark Trudeau as president of its Pharmaceuticals segment and a senior vice president of the Company, effective February 1. A 25-year pharmaceuticals industry veteran, Trudeau is president and chief executive officer of Bayer Healthcare, LLC.

Medical Suppliesfirst-quarter sales of $424 million were virtually unchanged from the $422 million reported in the comparable quarter of 2011, as increased sales of Nursing Care and Medical Surgical products countered decreases for SharpSafety and OEM products.

To view the full report and tables please click here.

Contacts

Covidien

Eric Kraus, 508-261-8305

Senior Vice President

Corporate Communications

eric.kraus@covidien.com

Bruce Farmer, 508-452-4372

Vice President

Public Relations

bruce.farmer@covidien.com

Coleman Lannum, CFA, 508-452-4343

Vice President

Investor Relations

cole.lannum@covidien.com

Todd Carpenter, 508-452-4363

Director

Investor Relations

todd.carpenter@covidien.com

DUBAI, United Arab Emirates – Saturday, January 28th 2012 [ME NewsWire]

Roche Diagnostics, diagnostic division of global healthcare company Roche announced that it will set up its Middle East headquarters in Jafza and commence operations next month. The announcement was made on the sidelines of healthcare exhibition and medical congress, Arab Health in Dubai today (xxx)

Although the global market leader in in-vitro diagnostics has been present in the Middle East region for more than 30 years, the Regional Headquarters in Jafza will be Roche Diagnostics’ first facility in the Middle East.

Through a strong distributor network, Roche Diagnostics has a presence in 18 markets in the Middle East with a 20-25% market share in all of these markets. Recognising the potential of the Middle East region, Roche Diagnostics seeks to increase the quality of supply and strengthen relations with distributors and end customers by providing added support and information. In the UAE, Roche Diagnostics enjoys a continuous relationship with its long-term distributor Pharmatrade through 30 years.

Ibrahim Aljanahi, Deputy CEO, Jafza and Chief Commercial Officer said: “We are pleased to host a respected Fortune 500 Company such as Roche at Jafza. Roche is a leader in research-focused healthcare with an impressive regional presence and we believe Jafza’s unmatched connectivity, logistics and commercial advantages will support its growth in the region. The new facility will be well positioned to serve the Roche’s growing customer base andhelp it further expand its regional footprint and market share. The new move reflects the company’s trust and confidence in Jafza and we extend our full support to Roche.”

“The Middle Eastern region is a very important part of our business. We see a tremendous potential for growth in the Middle East. Therefore, we decided to open our regional headquarters in Dubai as a hub to serve our Middle Eastern countries. I am very happy about this step. The unique combination of world-class port and airport facilities was one of the most significant reasons behind the decision to locate the Roche Diagnostics’ Middle East HQ in Jafza. Jafza is one of the leading drivers in the UAE economy and Roche Diagnostics will benefit from the advantages that come with being part of a growing business community.” says Dr. Michael Heuer, President EMEA-LATAM, Roche Diagnostics.

Roche Diagnostics, Middle East will serve distribution partners and customers across the region by setting up functions for scientific and technical support, management, administration, logistics and quality control. The office will be located in Jafza 15 and expects to see 50 employees working in the Middle East Regional Headquarters by 2013.

-Ends-

About Jafza

Jafza is Economic Zones World’s flagship operation. One of the world’s largest and the fastest growing free zones, Jafza is gateway to the Middle East, Africa and South Asian markets. Supported with excellent multi-modal logistics facilities, it offers customers excellent connectivity to reach the rapidly growing markets of over 2 billion people. Established in 1985, Jafza today is spread over an area of 57 sq. km and is home to over 6700 companies, including over 120 of the Fortune Global 500 enterprises, from across the world. It is a leading driver of the burgeoning UAE economy. With its impeccable track record, Jafza stands for innovation, customer centricity, transparent operations and entrepreneurial dynamism. For more information, visit www.jafza.ae.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Contacts

Adeti Changulani,

Hasaad Communications

Mob: +971 50 429 5576

adeti.changulani@hasaad.ae

Roche Diagnostics contact

Jane Prospero

Head of Communications EMEA-LATAM

jane.prospero@roche.com

Janne Nielsen

Communications Officer, Middle East

Janne.nielsen@roche.com

INGELHEIM, Germany – Thursday, January 26th 2012 [ME NewsWire]

(BUSINESS WIRE)– FOR NON-US MEDIA ONLY

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib* in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

Afatinib* is an irreversible ErbB Family Blocker which inhibits signal transduction of all kinase receptors from the ErbB Family, and is known to play a critical role in the growth and spread of the most pervasive cancers and cancers associated with high mortality (lung, breast, and head & neck cancers). Over-expression of the Epidermal Growth Factor Receptor (EGFR, also referred to as ErbB1)1 is found in at least 90% of head and neck cancers and strongly correlates with poor prognosis and overall survival.2

Positive results from a recently presented phase II study show that afatinib* is the first targeted therapy with at least comparable anti-tumour activity to cetuximab in patients with metastatic head and neck cancer whose cancer has returned (recurrent disease) after treatment with platinum-based chemotherapy.3

Each year, approximately 560,000 cases of head and neck cancer are diagnosed worldwide, and 300,000 patients die annually.4

For patients with recurrent/metastatic disease, treatment options include systemic chemotherapy. Despite the introduction of chemotherapy in this setting approximately 30 years ago, patients with recurrent/metastatic head and neck cancer still have a poor prognosis, with a median survival of only 6-10 months.5 In locally advanced head and neck cancer, chemoradiotherapy is an important option. However, due to high recurrence rates, patients with locally advanced disease tend to also have a poor prognosis.

“Currently, approximately 50% of patients with locally advanced head and neck cancer will have a recurrence and there is an urgent need for more treatment options” said Dr Ezra Cohen, Associate Professor of Medicine at the University of Chicago Medical Center “We hope potential new treatments such as afatinib will increase the effective options for patients with head and neck cancer.”

LUX-Head & Neck 1 will evaluate, if afatinib* can prolong progression-free survival (primary endpoint) and improve overall survival in patients with recurrent/metastatic head and neck cancer who progress after platinum-based treatment.

LUX-Head & Neck 2 will evaluate, if afatinib* can prevent the recurrence of the disease and improve overall survival in patients with locally advanced disease after chemoradiotherapy.

The initiation of these phase III clinical trials represents yet another important milestone for Boehringer Ingelheim to broaden and further develop its oncology pipeline across a range of different cancers.

This expands the phase III clinical trial programme for Boehringer Ingelheim Oncology which currently includes trials with afatinib* in NSCLC and breast cancer and nintedanib* (BIBF 1120) in NSCLC and ovarian cancer.

If investigators are interested in becoming involved in the study and have potentially eligible patients, they should contact Boehringer Ingelheim at:

clintriage.rdg@boehringer-ingelheim.com

Notes to editors

About Trial Nr. 1200.43 (LUX- Head & Neck 1) and Trial Nr 1200.131 (LUX -Head & Neck 2)

LUX- Head & Neck 1 (1200.43)

http://clinicaltrials.gov/ct2/show/study/NCT01345682

A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib* versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy

LUX-Head & Neck 2 (1200.131)

http://clinicaltrials.gov/ct2/show/NCT01345669

A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib* as adjuvant therapy after chemoradiotherapy in primary unresected HPV (Human Papilloma Virus) negative patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma

About Head and Neck Cancer

Head and neck cancer is the term used to describe malignant tumours originating in the upper aerodigestive tract (UADT), including the oral cavity, larynx, pharynx and nasopharynx. The vast majority (90%) of head and neck cancers are squamous cell carcinomas (HNSCC) arising from the epithelial membranes (mucus linings) of these regions,6 and as such they have many common features relating to their aetiology and classification. Additionally, the Epidermal Growth Factor Receptor (EGFR/ErbB1), which is critical for tumour growth,7 is over-expressed in at least 90% of head and neck cancers.2

Radiotherapy in combination with platinum-based chemotherapy (most often cisplatin) – administered either as a definitive treatment or after surgery – plays a role in the management of locally advanced and/or inoperable head and neck cancers; this is known as ‘chemoradiotherapy’. Chemoradiotherapy, however, is associated with significant side effects and toxicities. In addition, locally advanced head and neck cancer is associated with a poor prognosis due to high recurrence rates.8

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centres, Boehringer Ingelheim’s commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumours and haematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. Nintedanib* (BIBF 1120) is currently in phase III clinical development in NSCLC and Ovarian cancer. Afatinib* is currently in phase III clinical development in NSCLC and breast cancer. In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing an inhibitor of polo-like kinase 1 (Plk1), volasertib*, a protein that is involved in the processes of cell division.

Boehringer Ingelheim’s oncology pipeline is evolving and demonstrates the company’s continued commitment to the disease area.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion Euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit: www.boehringer-ingelheim.comor www.thewhiteroom.info

*Afatinib, nintedanib (BIBF 1120) and volasertib are investigational compounds. Their safety and efficacy have not yet been fully established.

References

1BI data on file

2Ford, A.C. and Grandis, J.R., 2003. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck, 25, 67-73

3Seiwert TY, et al. THNO 2011; Rome, abstract PP3.4

4Boyle P. et al. World Cancer Report 2008. International Agency for Research on Cancer.

5Coleman M.P et al. 2003 EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of Oncology, 14,S5, v128-v149.

6Viviana P. Lutzky. D. J. et al., 2008. Biomarkers for Cancers of the Head and Neck. Clinical Medicine: Ear, Nose and Throat, 1,5-15.

7Normanno N. et al., 2005. The ErbB receptors and their ligands in cancer: An overview. Current Drug Targets, May, 6(3), pp.243-247.

8Bernier, J. and Cooper, J.S. 2005. Chemoradiation after Surgery for High-Risk Head and Neck Cancer Patients: How Strong Is the Evidence? The Oncologist, 10(3), pp.215-224.

Contacts

Boehringer Ingelheim GmbH

Corporate / Global Media Contact

Julia Meyer-Kleinmann

Tel.: +49 (6132) 77-8271

PRESS@boehringer-ingelheim.com

More information

www.boehringer-ingelheim.com

(BUSINESS WIRE)– BIOTRONIK, a worldwide leader in manufacturing cardiac medical devices and pioneer of remote patient management solutions, today announced it has successfully completed its final interoperability testing process for BIOTRONIKHome Monitoring®, an Internet-based system for patient and implantable cardiac device information.

IHE “Connectathon”

During the week of January 9, 2012, BIOTRONIK participated in the “Integrating the Healthcare Enterprise” (IHE) North American Connectathon in Chicago, Illinois, to test its implantable device cardiac observation (IDCO) profile. This testing1 demonstrated the ability of BIOTRONIKHome Monitoring® to connect to third-party electronic health record (EHR) systems and cardiovascular data management systems using defined industry standards. The connecting technology from the BIOTRONIKHome Monitoring® system to the EHRs is called BIOTRONIK EHR DataSync®.

The conclusion from this successful testing is that BIOTRONIK EHR DataSync® will enable physicians and hospitals to share data seamlessly, which should increase productivity, eliminate redundant medical device management systems and improve clinical decision making and quality of care. In this round of testing, BIOTRONIK proved the ability of BIOTRONIK EHR DataSync® to connect with widely implemented EHR vendor systems (e.g., Epic and Medical Micrographics), as well as emerging and established cardiovascular data management systems (e.g., ScottCare’s OneView™ CRM).

The IHE developed their testing process to promote the adoption of standards that enable healthcare information to be shared seamlessly across clinical settings. The IHE’s goals are to drive standards for interoperability, to increase efficiency, and to reduce costs to healthcare customers, such as those in the cardiology, radiology and laboratory markets.

About BIOTRONIK EHR DataSync®

Implantable cardiac devices are also designed to capture and record information about medical device performance and patient heart rhythms that is vital to patient care.BIOTRONIKHome Monitoring® quickly organizes this information and allows data to be sent directly and securely to a clinic’s or a hospital’s EHR system. That data is then available to include in the patient’s personal health record.

“Electronic health records support efficient access to important patient healthcare information, so making this data readily available via secure data transport is vital,” said Jake Langer, President of BIOTRONIK, Inc. “Streamlined connectivity to critical device and lead data is an increasingly important priority for physicians and the broader U.S. healthcare network, and therefore BIOTRONIK made it a priority too. This demonstration of our system’s broad capabilities proves BIOTRONIK’s willingness and ability to provide yet another breakthrough, best-in-class innovation in accessing patient information.”

Data integrity is guaranteed and has been proven through validation testing. Data security is ensured by using U.S. Commerce Department encryption methods. In addition, the BIOTRONIKHome Monitoring® system adheres to patient privacy standards and requirements for the electronic transmission of health information in accordance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) standards.

About BIOTRONIK Home Monitoring®

BIOTRONIK Home Monitoring® is the first and only remote patient management system with FDA approval to replace device interrogation during in-office follow-up visits. BIOTRONIK Home Monitoring® allows for the safe reduction of conventional clinic follow-up visits and early detection of patient clinical events, based on results of the TRUST landmark trial.2–3

The system is unique because it allows continuous, automatic, wireless remote monitoring of patient and device status with daily updates—all independent from any patient interaction.

With immediate access to patient information through the secure BIOTRONIK Home Monitoring® website, physicians can remotely monitor and assess patient device data and determine the level of care needed. Alert notifications can be customized to fit each clinic’s workflow, helping to optimize clinic efficiency.

BIOTRONIK Home Monitoring® has pioneered advances in remote patient management since its first U.S. clinical application in 2001. Today, BIOTRONIK Home Monitoring® is extensively used with a growing number of patients in more than 3,800 clinics and 55 countries worldwide.

About BIOTRONIK SE & Co. KG

As one of the world’s leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of over 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.

More information:www.biotronik.com

References:

1 Data on file.

2 Varma N et al., Circulation, 2010, 122, 325–332.

3 Varma N et al., Circ Arrhythm Electrophysiol, 2010, 3:428–436.

Upon publication, please provide us with a copy.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50145161&lang=en

Contacts

BIOTRONIK SE & Co. KG

Sandy Hathaway

Senior Director, Global Communications

Tel. +49-(0)-30-68905-1602

Email: sandy.hathaway@biotronik.com